Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2022-10-24 Regulatory Filings
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
4DMedical releases CT LVAS in Australia 2 pages 266.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 25 October 2022 from 4DMedical Limited about the release of a new product, CT LVAS™, in Australia. It describes the product features, integration with existing networks, and the company's product pipeline. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a corporate announcement about a product release rather than a financial report, earnings release, or regulatory filing. It is also not a report publication announcement since it does not mention the release or availability of a report. Therefore, the document best fits the category of a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2022-10-24 English
4DMedical progresses towards full reimbursement in the US 2 pages 188.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 19 October 2022 from 4DMedical Limited regarding the acceptance of a new Category III CPT code by the American Medical Association for their XV Lung Ventilation Analysis Software. The content focuses on a regulatory and commercial milestone related to reimbursement and coding for medical procedures in the U.S. healthcare system. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a regulatory and commercial development rather than a financial report or detailed investor presentation. It is not a report publication announcement since it contains substantive information about the CPT code acceptance. The document fits best under the category of Capital/Financing Update (CAP) as it relates to a significant commercial and reimbursement development that impacts the company's capital and commercial prospects.
2022-10-18 English
Notification of cessation of securities - 4DX 4 pages 25.0KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from 4DMedical Limited regarding the cessation (lapse) of certain securities (options) due to conditions not being met. It details the number of securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is a regulatory announcement about changes in the company's issued securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement of changes in securities. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes including cessation of securities.
2022-10-12 English
Notification of Expiry of Unlisted Options 2 pages 319.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Notification of Expiry of Unlisted Options' dated 13 October 2022. It provides details about unlisted options expiring soon and updates on the company's capital structure, including the number of quoted and unquoted securities. The content focuses on capital structure changes and option expiries, which are related to financing and capital activities. The document is relatively short (3837 characters) and is a direct announcement rather than a detailed report or financial statement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-10-12 English
Change in substantial holding 5 pages 885.0KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Corporations Act 2001 Section 671B' and is a 'Notice of change of interests of substantial holder'. It details changes in voting power and relevant interests of a substantial shareholder in the company 4DMedical Ltd. The content includes dates, nature of changes, and number of securities affected, consistent with a major shareholding notification. There is no indication of financial statements, management discussion, or other report types. The document is regulatory in nature but specifically relates to changes in significant share ownership levels, matching the definition of Major Shareholding Notification (MRQ).
2022-10-12 English
Notice of Annual General Meeting/Proxy Form 31 pages 1.3MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Statement' for 4DMedical Limited's 2022 AGM. It includes details about the meeting date, location, agenda items such as receiving and considering the Financial Statements, Directors' Report, Auditor's Report, adoption of the Remuneration Report, election and re-election of directors, approval of option grants, renewal of takeover provisions, and approval of placement capacity. The document is a notice and explanatory statement sent to shareholders to inform them about the AGM and the resolutions to be voted on. It does not contain the actual financial statements or detailed financial data but rather serves as a meeting notice and proxy information. Therefore, it fits the category of AGM Information (AGM-R).
2022-10-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.